401 related articles for article (PubMed ID: 25435121)
1. Neuroblastoma: paradigm for precision medicine.
Irwin MS; Park JR
Pediatr Clin North Am; 2015 Feb; 62(1):225-56. PubMed ID: 25435121
[TBL] [Abstract][Full Text] [Related]
2. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma: biology, prognosis, and treatment.
Park JR; Eggert A; Caron H
Pediatr Clin North Am; 2008 Feb; 55(1):97-120, x. PubMed ID: 18242317
[TBL] [Abstract][Full Text] [Related]
4. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma.
Nakagawara A; Li Y; Izumi H; Muramori K; Inada H; Nishi M
Jpn J Clin Oncol; 2018 Mar; 48(3):214-241. PubMed ID: 29378002
[TBL] [Abstract][Full Text] [Related]
7. [Genetic alterations in neuroblastoma and their usefulness for clinical management].
Normand C; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Bull Cancer; 2011 May; 98(5):477-88. PubMed ID: 21609891
[TBL] [Abstract][Full Text] [Related]
8. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
Gustafson WC; Matthay KK
Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
[TBL] [Abstract][Full Text] [Related]
9. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.
Newman EA; Nuchtern JG
Semin Pediatr Surg; 2016 Oct; 25(5):257-264. PubMed ID: 27955728
[TBL] [Abstract][Full Text] [Related]
10. [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].
Pérel Y; Valteau-Couanet D; Michon J; Lavrand F; Coze C; Bergeron C; Notz A; Plantaz D; Chastagner P; Bernard F; Thomas C; Rubie H
Arch Pediatr; 2004 Jul; 11(7):834-42. PubMed ID: 15234382
[TBL] [Abstract][Full Text] [Related]
11. Stage 4N neuroblastoma before and during the era of anti-G
Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
[TBL] [Abstract][Full Text] [Related]
12. Cell death-based treatment of neuroblastoma.
Valter K; Zhivotovsky B; Gogvadze V
Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
[TBL] [Abstract][Full Text] [Related]
14. The quest to develop an effective therapy for neuroblastoma.
Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma: clinical and biological approach to risk stratification and treatment.
Tolbert VP; Matthay KK
Cell Tissue Res; 2018 May; 372(2):195-209. PubMed ID: 29572647
[TBL] [Abstract][Full Text] [Related]
16. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis of peripheral neuroblastic tumors.
Janoueix-Lerosey I; Schleiermacher G; Delattre O
Oncogene; 2010 Mar; 29(11):1566-79. PubMed ID: 20101209
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma: biology and staging.
Mueller S; Matthay KK
Curr Oncol Rep; 2009 Nov; 11(6):431-8. PubMed ID: 19840520
[TBL] [Abstract][Full Text] [Related]
19. Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
Park JR; Bagatell R; London WB; Maris JM; Cohn SL; Mattay KK; Hogarty M;
Pediatr Blood Cancer; 2013 Jun; 60(6):985-93. PubMed ID: 23255319
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma: Therapeutic strategies for a clinical enigma.
Modak S; Cheung NK
Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
